The most established of these is TRC105, an endoglin antibody that has been studied for the treatment of multiple solid tumor types, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, hepatocellular carcinoma and colorectal cancer (Rosen et al. Here, ENG is linked to hereditary clear cell renal cell carcinoma.